com)-- Ho Man Chan at Novartis will give a presentation on “Global Chromatin Profiling Leads to the Identification of NSD2 Mutations in Pediatric Acute Lymphoblastic Leukemia” at the 5th Cancer Targets & Therapeutics Conference to be held on July 7-8, 2014, in Boston, MA.

These findings identify NSD2 as a potential therapeutic target for Pediatric Acute Lymphoblastic Leukemia (ALL) and provide a general framework for the functional annotation of cancer epigenomes.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.